AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

Authors

Sarat Chandarlapaty

Memorial Sloan Kettering Cancer Center, New York, NY

Sarat Chandarlapaty , Hannah M. Linden , Patrick Neven , Katarina Petrakova , Aditya Bardia , Peter Kabos , Sofia A. D. S. Braga , Valentina Boni , Alice Gosselin , Sylvaine Cartot-Cotton , Séverine Doroumian , Marina Celanovic , Patrick Cohen , Gautier Paux , Mario Campone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03284957

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1058)

DOI

10.1200/JCO.2021.39.15_suppl.1058

Abstract #

1058

Poster Bd #

Online Only

Abstract Disclosures

FEATURED

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

Authors

Sarat Chandarlapaty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.